688735-01-5

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
(S)-tert-butyl 2-amino-2-cyclohexylacetate is used as a building block for the synthesis of novel drug candidates and bioactive molecules, due to its unique structure and functional groups that make it an attractive target for synthetic chemists and researchers in the pharmaceutical industry.
Used in Research and Development:
(S)-tert-butyl 2-amino-2-cyclohexylacetate is used as a subject of study for exploring its potential biological activities and pharmacological properties, as it may exhibit interesting characteristics that could be beneficial in the development of new medications and therapies.
Used in Chemical Synthesis:
(S)-tert-butyl 2-amino-2-cyclohexylacetate is used as a key intermediate in the synthesis of various complex organic compounds, leveraging its unique functional groups and structural features to facilitate the creation of new molecules with specific properties and applications.
Used in Drug Design:
(S)-tert-butyl 2-amino-2-cyclohexylacetate is used as a starting point for drug design, where its structural and functional attributes can be utilized to develop new therapeutic agents targeting specific diseases or conditions.

Upstream product

• 69901-75-3 (S)-[[(benzyloxy)carbonyl]amino](cyclohexyl)acetic acid 
• 1400472-52-7 C₁₉H₂₇NO₃ 

Downstream Products

• 1322615-45-1 Boc-Phe-Ser(Bz)-Chg-OtBu 
• 1322615-53-1 H-Phe-Ser(Bz)-Chg-OH*TFA 
• 1322615-77-9 benzoic acid 5-(S)-benzyloxycarbonylamino-2-(S)-[(1-(S)-tert-butoxycarbonyl-cyclohexyl-methyl)-carbamoyl]-4-oxo-6-phenyl-hexyl ester 
• 1322615-58-6 benzoic acid 5-(S)-amino-2-(S)-[(1-(S)-carboxy-cyclohexyl-methyl)-carbamoyl]-4-oxo-6-phenyl-hexyl ester trifluroacetate 

Relevant academic research and scientific papers

DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS

The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by lAPs. In particular the present compounds and compositions may be used to treat lAP-mediated ovarian cancer and hepatitis B infection.

Organocatalytic synthesis of optically active β-branched α-amino esters via asymmetric biomimetic transamination

This paper describes an efficient asymmetric biomimetic transamination of α-keto esters with a quinine-derived chiral base as the catalyst, giving a variety of β-branched α-amino esters in 50-96% yield and 87-95% ee. This journal is the Partner Organisations 2014.

IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS

Compounds of formula (IA) or (IB) are inhibitors of IkB kinase (IKK) activity, and are useful in the treatment of autoimmune and inflammatory diseases: Formula (A) and (B) wherein R7 is hydrogen or optionally substituted (C1-C6)alkyl; ring A is an optionally substituted aryl or heteroaryl ring of 5-13 ring atoms; Z is (a) a radical of formula R1R2CHNH-Y-L1-X1-(CH2)Z- wherein: z is 0 or 1; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular esterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non- natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(=O)NR3-, - C(=S)-NR3, -C(=NH)-NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent linker radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n, p, Q, AIk1 and AIk2 are as defined in the claims.

HDAC INHIBITORS

Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.